Esperion Therapeutics Inc
$ 3.30
-1.20%
24 Feb - close price
- Market Cap 798,472,000 USD
- Current Price $ 3.30
- High / Low $ 3.38 / 3.28
- Stock P/E N/A
- Book Value -2.20
- EPS -0.54
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -2.61 %
- 52 Week High 4.17
- 52 Week Low 0.69
About
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Analyst Target Price
$6.51
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-13 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-12 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-01 | 2023-05-09 |
| Reported EPS | 0 | -0.16 | -0.06 | -0.2063 | -0.1013 | -0.15 | -0.33 | 0.34 | -0.5 | -0.37 | -0.46 | -0.79 |
| Estimated EPS | 0.2916 | 0.02 | -0.14 | -0.15 | -0.1575 | -0.18 | -0.18 | 0.05 | -0.48 | -0.43 | -0.61 | -0.65 |
| Surprise | -0.2916 | -0.18 | 0.08 | -0.0563 | 0.0562 | 0.03 | -0.15 | 0.29 | -0.02 | 0.06 | 0.15 | -0.14 |
| Surprise Percentage | -100% | -900% | 57.1429% | -37.5333% | 35.6825% | 16.6667% | -83.3333% | 580% | -4.1667% | 13.9535% | 24.5902% | -21.5385% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ESPR
2026-02-24 12:52:08
Esperion (NASDAQ: ESPR) announced it will release its fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss the financial results and provide business updates. Esperion Therapeutics is a biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, currently marketing two non-statin therapies for LDL-C management.
2026-02-20 07:57:27
Principal Financial Group Inc. significantly reduced its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 51.7% during the third quarter, now owning 190,056 shares valued at $504,000. This move comes as other institutional investors have modified their positions, with insider Benjamin Halladay also selling shares. Esperion Therapeutics' stock is currently trading down 1.4% and has received mixed ratings from analysts, with a consensus of "Moderate Buy" and an average target price of $8.00.
2026-02-19 01:22:21
Esperion Therapeutics has settled another patent infringement lawsuit, this time with Alkem Laboratories, to prevent generic versions of its cholesterol-lowering drug bempedoic acid (Nexletol) from entering the market before patent expiration. The company, which gained FDA clearance for bempedoic acid in 2020, has previously reached similar settlements with several other generic manufacturers. Esperion still has pending lawsuits against additional pharmaceutical companies that filed Abbreviated New Drug Applications (ANDAs) for the drug.
2026-02-18 13:27:21
Esperion (NASDAQ: ESPR) announced its participation in the 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The webcast will be available live and as a replay on the company's investor relations website for 90 days. Esperion is a biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, currently marketing two oral non-statin therapies for high LDL-C.
2026-02-18 13:05:32
Esperion Therapeutics, Inc. announced its participation in the 2026 Citizens Life Sciences Conference, scheduled for March 11, 2026, at 8:25 a.m. ET. A live webcast will be available on Esperion's investor and media website, with a replay accessible for approximately 90 days afterward. Esperion is a commercial-stage biopharmaceutical company focused on developing and delivering innovative cardiovascular and rare disease therapies.
2026-02-17 13:28:10
Esperion Therapeutics has entered into a settlement agreement with a fifth generic drug applicant, which prevents the generic marketing of its drugs Nexletol and Nexlizet before April 19, 2040. This agreement strengthens the market exclusivity for Esperion's key products, expected to positively impact the company's future revenue prospects. The drugs are crucial for treating hypercholesterolemia.
